Page 21 - சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Buzz Show: Arcturus Therapeutics (NASDAQ: ARCT) Shares Fall After Analyst Downgrade Stock

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Arcturus Therapeutics Shares Fall After Analyst Downgrade Stock” Arcturus Therapeutics (NASDAQ: ARCT) plunged over 41% after analysts downgraded the company on disappointing results from a Phase 1/2 trial of its COVID-19 vaccine candidate. Even though the company had been granted approval from the Singapore Health Sciences Authority to move ahead with a Phase 2 study, analysts were worried that the candidate would not be able to achieve competitive levels of vaccine efficacy with single-shot dosing. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes s

United statesSan diegoSingapore health sciences authorityArcturus therapeutics holdings incMrna technologyBuzz showFeaturing our corporate news recapTherapeutics shares fall after analyst downgradeArcturus therapeutics holdingsOrnithine transcarbamylaseCystic fibrosisCardiovascular diseaseGlycogen storage disease typeHepatitisb virusஒன்றுபட்டது மாநிலங்களில்சான் டியாகோ

Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates

Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for Arcturus on Tuesday. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021, on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. Barclays analyst Gena Wang wrote that the interim data of the vaccine candidate was disappointing, per Seeking Alpha. Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company s COVID-19 vaccine updates. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies.

Raymond jamesYasmeen rahimiPiper sandlerGena wangSingapore health sciences authorityArcturus therapeuticsWall streetAnalyst gena wangJason teedVaccine trialsVaccine candidatesStock marketCovid vaccineArcturus stock priceArcturus stockரேமஂட் ஜேம்ஸ்

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEng eongCarlo tanziSteve hughesNeda safarzadehUltragenyx pharmaceutical incInfectious diseases programmeJanssen pharmaceuticals incArcturus therapeutics holdings incCystic fibrosis foundationJanssen pharmaceutical companies of johnsonTakeda pharmaceutical companySingapore health sciences authoritySynthetic genomics incMrna technology

INEX Innovate s CORO Real-Time RT-PCR SARS-CoV-2 Kit for the detection of COVID-19 obtains Singapore s Health Sciences Authority Provisional Authorisation

(2) The COVID-19 pandemic has seen in excess of 81 million confirmed cases globally and more than 1.7 million deaths and rising daily (1) CORO Real-Time RT-PCR SARS-CoV-2 for the diagnosis of COVID-19, was developed based on three genes recommended by the World Health Organisation (WHO) Singapore s Health Sciences Authority has given provisional authorisation for CORO to be used in Singapore. SINGAPORE, Dec. 29, 2020 /PRNewswire/ INEX Innovate Pte Ltd a Singapore based molecular diagnostics developer today announced that the Singapore Health Sciences Authority has issued provisional authorisation to the company s CORO Real-Time RT-PCR SARS-CoV-2 for the diagnosis of COVID-19. CORO TM Real-Time RT-PCR SARS-CoV-2 kit is a multiplex real-time molecular diagnostic test for diagnosis of SARS-CoV-2 in accordance to WHO and Centre of Disease Control recommendations whereby several genes are used for positive diagnosis.

United statesHong kongUnited kingdomNational university of singaporeSingapore generalKane blackKostenloser wertpapierhandelWomen life science health innovationsGene laboratoryPte ltda singaporeWorld health organisationSingapore health sciences authorityCentre of diseaseBritish chamberHealth sciences authorityPte ltd

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Hong kongKeith grossmanChristopher peetzWilliam liangNovo nordiskZai labVirios therapeuticsGilead sciences incAprea therapeutics incLiquidia corpZai lab licensed ovarian cancer drug eligibleZai lab ltdAlkermes plcBristol myers squibb coInhibikase therapeutics incEuropean medicines agency for ozempic